OGEN Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
2.6M
+14.9%
2.3M
-9.7%
2.5M
-20.0%
3.1M
+82.2%
1.7M
R&D
1.2M
+82.3%
645.5K
-3.7%
670.5K
-28.0%
930.9K
+107.0%
449.7K
SG&A
1.4M
-12.1%
1.6M
-11.9%
1.8M
-16.7%
2.2M
+73.4%
1.3M
Operating Income
-2592528
-14.9%
-2255927
+9.7%
-2498301
+20.0%
-3123773
-82.2%
-1714202
EBITDA
-2592528
-14.9%
-2255927
+9.7%
-2498301
+20.0%
-3123773
-82.2%
-1714202
Net Income
-2528707
-14.9%
-2201243
+3.7%
-2286870
+25.4%
-3066589
-35.0%
-2272035
EPS (Basic)
$-0.57
-11.8%
$-0.51
-27.5%
$-0.40
+79.6%
$-1.96
+36.8%
$-3.10
EPS (Diluted)
$-0.57
-11.8%
$-0.51
-27.5%
$-0.40
+79.6%
$-1.96
+36.8%
$-3.10
Shares (Diluted)
4.4M
+3.0%
4.3M
-24.9%
5.7M
+267.0%
1.6M
+113.3%
731.8K
Oragenics (OGEN) — Financials